Bali, 19 June 2024, Bali International Hospital, a subsidiary of PT Pertamina Bina Medika Indonesia Healthcare Corporation (“IHC”), and Icon Asia Holdings Pte Ltd (“ICON”), a subsidiary of global cancer care provider Icon Group ̶ Australia’s largest provider of private cancer care services – has signed a Memorandum of Understanding (“MOU”) on 6 June, 2024 to enhance the quality of oncology care for the people of Indonesia.

The MOU was signed by dr. Dewi F. Fitriana, MPH, Chief Executive Officer of Bali International Hospital (“BIH”) and Ms. Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong, as part of a shared commitment to explore the provision of chemotherapy compounding, oncology pharmacy, expertise in medical oncology delivery and other oncology services at BIH.

“We recognise the urgent need to address the escalating cancer rates in Indonesia, where it stands as the second leading cause of death among non-communicable diseases,” stated dr. Dewi F. Fitriana, MPH. “Our partnership with Icon marks a crucial step towards bridging the gap in cancer care. Together, we are committed to delivering world-class oncology services that will significantly improve healthcare outcomes for the Indonesian population.”

Advanced technology and equipment will underpin the BIH cancer care offering, including 3D-mammography, 3.0 Tesla MRI, 256-slice CT and a PET-CT to support cancer diagnostics. This will be combined with a Varian TrueBeam and SagiNova Brachytherapy to advance cancer treatment capability. This MOU will enable BIH to leverage Icon’s expertise in establishing world-class oncology services to enable best-in-class, patient-centred care at BIH.

BIH not only aims to improve the quality of healthcare in Indonesia, but also to make Indonesia a global health tourism destination. By combining health tourism and high-quality medicine, BIH is expected to attract tourists and patients from abroad to come to Indonesia.